Plasma catecholamine concentrations were measured in 15 patients (six male) aged 14-63 years attending the casualty department with acute severe asthma (peak expiratory flow 27% (SEM 3%) of predicted). Nine patients were admitted and six were not. The plasma noradrenaline concentration, reflecting sympathetic nervous discharge, was two to three times normal In all patients and was significantly higher in those who required admission compared with those discharged home (mean 7-7 (SEM 0-6) v 4-7 (0-5) nmol/l (1-3 (SEM 0-1) v 0-8 (0-08) ng/ml); p <0 001). Plasma adrenaline concentradon, however, was not. increased in any patient. This surprising failure of the plasma adrenaline concentration to increase during the stress of an acute attack of asthma was unexplained and contrasts with the pronounced rise in plasma adrenaline and noradrenaline concentrations in acute myocardial infarction, heart failure, and septicaemia.
Introduction
Adrenaline has been used as a bronchodilator since early this century,' and it is still the first line treatment for acute severe asthma in many countries. Investigation of the role of endogenous adrenaline in the regulation of airway smooth muscle tone has become possible only with the recent development of sensitive and specific assays.2 3 ( Adrenoceptor antagonists exacerbate bronchoconstriction in asthmatic patients, suggesting that their airway ( receptors are normally under tonic stimulation. In the absence of a functional sympathetic innervation to bronchial smooth muscle in man4 it has been suggested that endogenous circulating adrenaline activates these airway ( receptors,6 Plasma catecholamine concentrations in resting stable asthmatic subjects are normal," however, and probably too low to account for resting ( adrenergic tone. There is no information about sympathoadrenal activation during acute exacerbations of asthma, when endogenous catecholamines would be expected to be recruited to promote bronchodilatation in the same way that adrenaline and noradrenaline act to stimulate the failing heart7 or counteract the cardiovascular changes of septicaemic shock.8 We report the first measurements of plasma adrenaline and noradrenaline concentrations during the stress of acute severe asthma.
Patients and methods
We studied 15 patients aged 14-63 years (mean 31) who attended the casualty department with acute exacerbations of asthma. In all the diagnosis of asthma was established on the basis of a history of reversible airflow obstruction and a documented >20% improvement in forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEF), either spontaneously or after salbutamol. Six of the patients were male, and 11 were atopic on skin prick testing with common antigens. Nine of-the patients required admission on clinical criteria (group 1) and six (group 2) did not. All patients were taking regular inhaled P agonists, 12 took inhaled steroids, two took regular cromoglycate, and four took oral theophyllines. None had taken oral steroids within the past month, and none received aminophylline or any other drug before blood sampling. All made an uneventful recovery.
Heart rate was measured by 30 second radial pulse count, and blood pressure by sphygmomanometry, and pulsus paradoxus was determined in duplicate. PEF was measured using a Wright peak flow meter. Arterial blood gas values and pH were determined when clinically indicated.
After initial assessment an intravenous cannula was sited and oxygen (24-60%) administered through a facemask while a solution of a P2 agonist (salbutamol 5 mg) was prepared for nebulisation. At that stage, with the patient semirecumbent, a 3 ml blood samplethat is, in addition to the clinical sample (15 ml)-was drawn into a heparinised tube on ice, the plasma being separated within 15 minutes and stored in duplicate at -80°C until assay. Consent to remove the extra 3 ml of blood was obtained verbally in each case. Patients were reassessed 15-30 minutes after nebuliser treatment and a decision made regarding hospital admission and further management as an inpatient or outpatient. Arterial blood gas tensions were measured if admission was recommended. Results were expressed as the arterial to alveolar oxygen tension ratio (a:Ao.), which allows comparison between patients receiving differing inspired oxygen concentrations.9 Plasma catecholamine concentrations were measured by a double isotope enzymatic technique, which is specific and has a sensitivity of 0-05 nmol/l (0-01 ng/ml) and an intra-assay coefficient of variation of 10%. 3 Results are expressed as means and standard error of the mean (SEM). Statistical tests included paired and unpaired t tests and the Mann-Whitney U test.
in normal subjects.6 Plasma adrenaline concentrations in these acute asthmatics were at the lower end of the range that we have measured in normal or in asthmatic subjects.
There was no significant correlation of plasma catecholamine concentrations with PEF, heart rate, systolic blood pressure, pulsus paradoxus, or blood gas tensions. (fig 2) . The mean concentration was 7-74 (SEM 0 59) nmol/l (1-31 (SEM 0-10) ng/ml) in group 1 and 4-67 (0 47) nmol/l (0-79 (0 08) ng/ml) in group 2. It was significantly higher in patients who required admission than in those who did not (p <0.001). Plasma adrenaline concentrations, however, were not raised in either group: the mean value was 0-23 (SEM 0-04) nmol/l (0{04 (SEM 0-007) ng/ml) in group 1 compared with 0-27 (009) nmol/l (0-05 (0-016) ng/ml) in group 2. Normal values in our laboratory for seated subjects range from 10 to 5 0 nmol/l (017 to 0-85 ng/ml) for noradrenaline and from 0 2 to 1 0 nmol/l (0-04 to 0-18 ng/ml) for adrenaline. In several studies in 43 resting stable asthmatic subjects (FEV, >70% of predicted) we have determined the mean noradrenaline concentration as 2-78 (0-12) nmol/l (0 47 (0 02) ng/ml) and mean adrenaline concentration as 0-29 (0 04) nmol/l (0 05 (0 007) ng/ml). These is there the failure to respond to the stress of severe, possibly life threatening, bronchoconstriction but in acute severe asthma it would be expected that all possible dilator mechanisms would be recruited. Adrenaline is the most potent endogenous bronchodilator and yet circulating concentrations remained in the low normal range-well below those necessary to produce bronchodilatation in asthma."
This surprising failure to increase plasma adrenaline concentration might be explained by exhaustion of adrenaline production by the adrenal gland, by an impairment of release, or possibly by an increased clearance of adrenaline from the circulation. Depletion of adrenaline is extremely unlikely, as the duration of the asthmatic attack in some of these patients was only a few hours and increased adrenaline secretion in myocardial infarction is known to persist for over 12 hours.'0 Clearance of adrenaline from the circulation is rapid"3 and does not appear to be increased, certainly not in patients with stable asthma."9 Impairment of adrenaline release may be a more likely explanation of our findings, as there is other evidence for this in asthma. Although plasma catecholamine concentrations in stable asthma are normal,6 there is evidence of reduced adrenaline excretion in response to mental stress'4 and also a blunted rise in noradrenaline and a block of the normal increase in circulating adrenaline on treadmill exercise of asthmatic compared with control subjects.5 16 Impaired catecholamine release is partial, however, since more profound stimuli such as hypoglycaemia ' or more strenuous exercise" or histamine infusion'7 produce a normal plasma catecholamine response in asthma. Previous ( adrenergic bronchodilator treatment is unlikely to explain the low adrenaline concentrations, since large oral doses of salbutamol have no effect on plasma adrenaline values." ' When acute bronchoconstriction is induced experimentally by isocapnic hyperventilation,"5 exercise,"5 16 propranolol, 20 or antigen bronchoprovocation 2 there is a similar failure to increase circulating adrenaline concentrations, though this would be expected to alleviate airway narrowing. In this study of acute severe asthma plasma noradrenaline concentrations were increased as anticipated but, though adrenaline secretion as a bronchodilatator mechanism would be expected, there was a surprising failure of the plasma adrenaline concentration to increase. This may be due to impaired secretion of adrenaline in asthma, although the mechanism remains uncertain.
Introduction Serum angiotensin converting enzyme activity has been studied extensively in patients with sarcoidosis and has been used both as a diagnostic test and in assessing the activity of the disease.' Serum activities tend to be high in acute disseminated disease when corticosteroid treatment has been withheld.2 Sarcoidosis
